

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number
WO 03/030824 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US02/31998

(22) International Filing Date: 7 October 2002 (07.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/327,673 5 October 2001 (05.10.2001) US

(71) Applicant: **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, MA 02114 (US).

(72) Inventor: **PODOLSKY, Daniel, K.**; 15 Edmunds Road, Wellesley, MA 02481 (US).

(74) Agent: **CLARK, Paul, T.**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR TREATING DERMAL LESIONS

(57) Abstract: This invention features methods of treating and preventing damage to the epidermis and dermis by local administration of trefoil peptides. The trefoil peptide can be administered either alone or in combination with other therapeutics including antimicrobial agents, anti-inflammatory agents or, analgesics.



WO 03/030824 A2

5 METHODS AND COMPOSITIONS FOR TREATING DERMAL LESIONS

Field of Invention

This invention relates to methods and compositions for treating and
10 preventing lesions of the skin in a mammal that can result from traumatic,
infective, physiologic, or pathologic causes.

Background of the Invention

Full thickness wounds of the skin can result from various causes, the most
15 common of which are traumatic or surgical lesions. Partial thickness wounds are
commonly caused by abrasions, burns, pressure injuries, or other minor trauma.
Skin epithelial destruction can also be a consequence of cancer chemotherapy or
radiotherapy of the skin. Skin lesions can further result from a hypersensitive
reaction to a therapeutic agent either administered topically or systemically. In
20 addition to those drugs which can cause direct damage, certain drugs including
many antibiotics, can induce skin photosensitivity, which may in turn lead to
epithelial lesions. Alternatively, wounds and ulcers can also result from vascular
insufficiency; from chronic diabetes, which is often characterized by vascular
diseases; as well as from pressure necrosis and bedsores.

25 Typically, routine wound care is directed at reducing infection, ensuring an
adequate arterial supply and venous drainage, and in cases of moderate or severe
injury, ensuring the close approximation of the epithelial surfaces by mechanical
methods (e.g., sutures or wound clips). In this regard, secondary infections by
pathogenic microorganisms are important to consider, particularly in light of the
30 protective barrier function of the skin. These conditions, when severe, are risk
factors for chronic debilitating local infections and septicemias as
microorganisms may use the compromised epithelium as a portal of entry into the
body. Secondary infections may be further exacerbated in immunocompromised

patients, such as those undergoing cancer treatment (chemotherapy or radiotherapy).

In addition to the functional restoration of the dermal barrier, wound care is further concerned with the cosmetic outcome and the reduction of scar tissue.

- 5 As such, the rapid restoration of a normal epithelial layer has the potential to reduce the amount of scar formation and secondary complications of the wound, particularly infections.

Summary of the Invention

- 10 This invention features the treatment and prevention of lesions of the skin of a mammal by administration to the lesion, or regions of the skin where a lesion is to be prevented, therapeutically effective amounts of a trefoil peptide, or a biologically active fragment thereof. Treatment or prevention of lesions according to the invention can speed healing, reduce pain, delay or prevent
- 15 occurrence of the lesion, and inhibit expansion, secondary infection, or other complications of the lesion. Preferably, the mammal is a human. In particularly useful embodiments, the trefoil peptide is spasmodic peptide (SP), pS2, Intestinal Trefoil Peptide (ITF), ITF₁₅₋₇₃, ITF₂₁₋₇₃, ITF₁₋₇₂, ITF₁₅₋₇₂, or ITF₂₁₋₇₂, and is present in a pharmaceutical composition containing a pharmaceutically
- 20 acceptable carrier. Other useful trefoil peptides include polypeptides that are substantially identical to SP, pS2, ITF, ITF₁₅₋₇₃, ITF₂₁₋₇₃, ITF₁₅₋₇₂, or ITF₂₁₋₇₂. Preferably, the trefoil peptide is ITF or a biologically active ITF fragment, which may be administered as a monomer, a dimer, or another multimeric form.

- The methods and compositions of this invention are particularly useful for
- 25 treating lesions of the skin caused by an inflammatory or allergic reaction such as eczema, psoriasis, or contact dermatitis; pressure ulcers, acne, lesions caused by physical trauma or surgical intervention (e.g., local biopsy or cut), lesions caused by chemical, thermal or radiation burns, or lesions caused by antineoplastic therapy (e.g., chemotherapy or radiation therapy). Additionally, lesions of the
- 30 skin that result from microbial infections, whether bacterial, viral (e.g., herpes or papilloma virus) or fungal, are also amenable to treatment. More specifically,

administration of trefoil peptides is also useful for treating lesions or promoting epithelial growth and maturity in preterm infants whose epidermis is in an immature state.

In the methods and compositions, a second therapeutic agent can be included. Desirable second therapeutic agents include anti-inflammatory agents (e.g., rofecoxib or celecoxib), antibacterial agents (e.g., benzoyl peroxide, povidone iodine, azelaic acid, retinoids, clindamycin, erythromycin, penicillins, cephalosporins, tetracyclines, and aminoglycosides), antifungal agents (e.g., nystatin, amphotericin B, benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazole, allylamine, and thiocarbamate), antiviral agents (e.g., acyclovir), topical analgesics (e.g., lidocaine and benzocaine), systemic analgesics (e.g., opiates, fentanyl, and NSAIDs), steroids (e.g., triamcinolone, glucocorticoid, budesonide, fluocinolone, betamethasone, diflucortolone, fluticasone, mometasone, prednisone, methylprednisolone, betamethasone, dexamethasone, triamcinolone, and hydrocortisone), and ultraviolet blocking agents. Sedatives, such as the benzodiazepines (e.g., diazepam), may also be administered systemically in severe cases of shock associated with dermal trauma. Trefoil peptides when administered for the treatment of psoriasis may include topical agents (e.g., anthralin, retinoids, vitamin D analogues, and glucocorticoids) or systemic agents (e.g., methotrexate and cyclosporine). The second therapeutic agent may be administered within (either before or after administration of the trefoil peptide) 14 days, 7 days, 1 day, 12 hours, 1 hour, or simultaneously with the trefoil peptide.

The second therapeutic agent can be present in the same or different pharmaceutical compositions as the trefoil peptide. When the second therapeutic agent is present in a different pharmaceutical composition, different routes of administration may be used. For example, the second therapeutic may be administered orally, or by intravenous, intramuscular, or subcutaneous injection. Thus, the second therapeutic need not be administered topically.

30

Of course, pharmaceutical compositions may contain two, three, or more trefoil peptides or biologically active fragments. Alternatively, topical administration of the trefoil peptide may be supplemented by oral administration of the same or a different trefoil peptide.

5 The compositions of this invention can also be used prophylactically, prior to therapies or conditions that will damage the dermis or epidermis. For example, the compositions can be applied to an area of the skin prior to cancer therapy in order to mitigate the loss of epidermal integrity. Compositions containing a trefoil peptide can also be applied to an area of the skin prior to sun exposure or
10 prior to a surgical intervention.

 Suitable pharmaceutical compositions include at least one trefoil peptide and a pharmaceutically acceptable carrier. Treatment using trefoil peptide-containing compositions of this invention is typically self-administered. However, trefoil peptide therapy may be administered by a medical professional
15 or other health care provider. For example, a trefoil peptide-containing gel, cream, solution, suspension, ointment, spray, bioerodable polymer, or hydrogel (non-bioerodable polymer) may be applied to lesions caused by the removal of a malignant lesion immediately after a surgical or laser removal procedure. In other useful embodiments, a mucoadhesive, an osmotic agent, or viscosity-enhancing
20 agent is present. Alternatively, the trefoil peptide can be formulated for topical application as a concentrated paste, suspension, a cream, or an ointment to be applied directly to the lesion. Alternatively, the trefoil peptide can be formulated as a topical patch to provide sustained delivery of the peptide. This patch may or may not be adhesive, and may or may not be occlusive. An occlusive patch may
25 increase the permeability of trefoil peptide through a partially denuded epithelium. Other occlusive excipients (e.g., hydrophobic polymers) and also penetration enhancers (fatty acids, alcohols, benzoates, glycols, or pyrrolidones) may also be used to enhance trefoil penetration. Furthermore, the trefoil peptide can be formulated to irrigate a wound prior to suturing or during a surgical
30 procedure. The trefoil peptide may therefore be formulated in an irrigation solution such as saline or Ringer's solution. Alternatively, trefoil peptides can be

impregnated in suture material (gut, silks, collagens, glycolic acid polymers or nylon) or wound dressings (gauze pads, occlusive dressings, semi-occlusive dressings, alginates, hydrocolloids and adhesive films).

Mammalian trefoil peptides were discovered in 1982. One of the
5 mammalian trefoil peptides, human intestinal trefoil factor (ITF; TFF3), has been characterized extensively, and is described in U.S. Patent Nos. 6,063,755, and 6,221,840, hereby incorporated by reference. The other two known human trefoil peptides are spasmolytic polypeptide (SP; TFF2) and pS2 (TFF1). Trefoil
10 peptides, described extensively in the literature (e.g., Sands *et al.*, Annu. Rev. Physiol. 58: 253-273, 1996), are expressed in the gastrointestinal tract and have a three-loop structure formed by intrachain disulfide bonds between conserved cysteine residues. These peptides protect the intestinal tract from injury and can be used to treat intestinal tract disorders such as peptic ulcers and inflammatory
15 bowel disease. Homologs of these human peptides have been found in a number of non-human animal species. All members of this protein family, both human and non-human, are referred to herein as trefoil peptides. Human ITF will be referred to most extensively in this application; however, the activity of human ITF is common to each of the mammalian trefoil peptides.

“Trefoil peptide,” as used herein, includes all mammalian homologs of
20 human spasmolytic polypeptide (SP; also known as TFF2), human pS2 (also known as TFF1) and human intestinal trefoil factor (ITF; also known as TFF3), and biologically active fragments thereof. Homologs of the trefoil peptides have, preferably, 70% amino acid identity to the human sequence, more preferably 85% identity, most preferably 95%, or even 99% sequence identity. The length of
25 comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues. Alternatively, trefoil peptides are polypeptides encoded by a polynucleotide that hybridizes with high stringency to the human ITF, pS2, or SP
30 cDNAs provided in SEQ ID NOs: 4, 5, and 6, respectively, or the human ITF, pS2, or SP genes provided in SEQ ID NOs: 7, 8, and 9, respectively.

The term "fragment" is meant to include polypeptides that are truncations or deletions of SP, pS2 and ITF. Preferably, the fragments are biologically active and have 70% amino acid identity to the corresponding regions of the human polypeptide sequence. More preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence to which they correspond. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

Preferable fragments contain four cysteine residues in any positions which correspond to the cysteines at positions 25, 35, 45, 50, 51, 62, or 71, of human ITF (Figure 1), or positions 31, 41, 51, 56, 57, 68, and 82 of human pS2 (Figure 2). More preferably, fragments contain five cysteine residues at these positions. Most preferably, six, or even all seven cysteines are present.

Fragments of SP are meant to include truncations or deletions and preferably have 70% sequence identity to the corresponding human SP polypeptide sequence (Figure 3). More preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence. Preferably, active fragments contain at least four cysteine residues, which correspond to positions 6, 8, 19, 29, 34, 35, 46, 58, 68, 78, 83, 84, 95, and 104 in the human SP polypeptide. More preferably, fragments contain six cysteines, which correspond to these positions. Even more preferable are fragments that contain eight cysteines. Most preferable are fragments that contain cysteines at ten, twelve, or even, all fourteen positions.

It is recognized in the art that one function of the identified cysteine residues is to impart the characteristic three-loop (trefoil) structure to the protein. Accordingly, preferred fragments of ITF and pS2 have a least one loop structure, more preferably, the fragments have two loop structures, and most preferably, they have three loop structures. It is equally well recognized that the native SP polypeptide has a six loop confirmation. Preferable fragments contain at least

two of these loop structures, more preferably, four loop structures are conserved, and most preferably, five, or even all six loop structures are present.

By "co-formulated" is meant any single pharmaceutical composition, which contains two or more therapeutic or biologically active agents.

5 By "pharmaceutical preparation" or "pharmaceutical composition" is meant any composition, which contains at least one therapeutically or biologically active agent and is suitable for administration to a patient. For the purposes of this invention, pharmaceutical compositions suitable for delivering a therapeutic to the skin include, but are not limited to aqueous solutions, creams, 10 gels, suspensions, sprays, bioerodable polymer, hydrogel (non-bioerodable gel polymer), patches, irrigation solution, pastes, lotions, ointments, foams, wound dressings, and sutures. Any of these formulations can be prepared by well-known and accepted methods of art. See, for example, Remington: The Science and Practice of Pharmacy, 19th edition, (ed. AR Gennaro), Mack Publishing Co., 15 Easton, PA, 1995.

By "topical administration" is meant the application of a therapeutically effective amount of pharmaceutical composition to the external and/or exposed surface of the skin, to access the dermis and/or epidermis.

By "therapeutically effective amount" is meant an amount sufficient to 20 provide medical benefit. When administering trefoil peptides to a human patient according to the methods described herein, an effective amount will vary with the size of the lesion area being treated; however, a therapeutically effective amount is usually about 1-2500 mg of trefoil peptide per dose. Preferably, the patient receives at least 10 mg, 100 mg, 500 mg, 750 mg, 1000 mg, 1500 mg, or 2000 mg 25 of trefoil peptide in each dose. Larger amounts may be required for large lesions such as those caused by extensive thermal burns. Dosing is typically performed 1-5 times each day.

By "biologically active," when referring to a trefoil peptide, fragment, or homolog is meant any polypeptide that exhibits an activity common to its related, 30 naturally occurring family member, and that the activity is common to the family of naturally occurring trefoil peptides. An example of a biological activity

common to the family of trefoil peptides is the ability to reconstitute the gastrointestinal mucosa (Taupin *et al*, *Proc. Natl. Acad. Sci. U S A.* 97(2): 799-804).

By "isolated DNA" is meant DNA that is free of the genes, which in the naturally occurring genome of the organism from which the given DNA is derived flank the DNA. Thus, the term "isolated DNA" encompasses, for example, cDNA, cloned genomic DNA, and synthetic DNA.

By "treating" is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The active ingredients of the pharmaceutical composition can treat the primary indication (e.g., epithelial lesion) or secondary symptoms (e.g., concomitant infection, pain, or inflammation).

By "burn" is meant any injury to the dermis, epidermis, or underlying tissue that results from exposure to heat, acids, caustics, chemicals, electricity, or radiation (e.g., ultraviolet radiation), marked by varying degrees of skin destruction and hyperemia often with the formation of watery blisters and in severe cases by charring of the tissues, and classified according to the extent and degree of the injury. There are three classifications of burns. A first-degree burn is superficial, involving only the top layer of the skin (epidermis). First-degree burns are characterized by dry, red skin, and typically heal within 5-6 days without permanent scarring. A second-degree burn is a partial thickness burn, involving the epidermis and the dermis. These burns will blister and weep, and in the absence of therapy, usually require 3-4 weeks or longer to heal. Scarring may occur. The most severe, third-degree burn, destroys all skin layers, and some of the underlying tissue. Complications of shock and infection make a third-degree burn potentially life threatening.

By "wound dressing" is meant any occlusive or semi-occlusive covering that overlay a lesion or injury site. In addition to providing contact of the skin with a trefoil peptide, preferable dressings maintain a moist environment at the lesion site, remove excess exudates, have thermal insulation properties, allow gaseous exchange, are impermeable to microorganisms, and/or allow trauma-free

removal. The choice of dressing will be influenced, for example, by clinical indications such as the type of wound, wound position, presence of debris or infection, level of exudate, patient comfort, and cost efficiency.

By “antimicrobial agent” is meant any compound that alters the growth of bacteria or fungi cells, or viruses whereby growth is prevented, stabilized, or inhibited, or wherein the microbes are killed. In other words, the antimicrobial agents can be microbiocidal or microbiostatic.

By “antineoplastic therapy” is meant any treatment regimen used to treat cancer. Typical antineoplastic therapies include chemotherapy and radiation therapy.

By “ultraviolet blocking agent” is meant any treatment regimen used to block ultraviolet radiation. Typical ultraviolet radiation blockers are formulated as creams or pastes to be applied before sun exposure.

By “substantially identical” is meant a polypeptide or nucleic acid exhibiting at least 75%, but preferably 85%, more preferably 90%, most preferably 95%, or 99% identity to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 20 amino acids, preferably at least 30 amino acids, more preferably at least 40 amino acids, and most preferably 50 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 60 nucleotides, preferably at least 90 nucleotides, and more preferably at least 120 nucleotides.

By “high stringency conditions” is meant any set of conditions that are characterized by high temperature and low ionic strength and allow hybridization comparable with those resulting from the use of a DNA probe of at least 40 nucleotides in length, in a buffer containing 0.5 M NaHPO₄, pH 7.2, 7% SDS, 1mM EDTA, and 1% BSA (Fraction V), at a temperature of 65 C, or a buffer containing 48% formamide, 4.8X SSC, 0.2 M Tris-Cl, pH 7.6, 1X Denhardt’s solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42°C. Other conditions for high stringency hybridization, such as for PCR, Northern, Southern, or in situ hybridization, DNA sequencing, etc., are well known by those skilled in the art of molecular biology. See, e.g., F. Ausubel et al., Current

Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1998, hereby incorporated by reference. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

5 Brief Descriptions of the Drawings

Figure 1 is an amino acid sequence of a human intestinal trefoil factor (ITF; Accession No. BAA95531).

Figure 2 is an amino acid sequence of a human pS2 protein (Accession No. NP_003216).

Figure 3 is an amino acid sequence of human spasmolytic polypeptide (SP; Accession No. 1909187A).

Figure 4 is a cDNA sequence encoding a human intestinal trefoil factor.

Figure 5 is a cDNA sequence encoding a human pS2 protein.

Figure 6 is a cDNA sequence encoding a human spasmodic polypeptide.

15 Figure 7 is the nucleotide sequence of a gene encoding human intestinal trefoil factor (locus 10280533:52117-55412).

Figure 8 is the nucleotide sequence of a gene encoding human pS2 protein (locus 10280533:16511-21132).

Figure 9 is the nucleotide sequence of a gene encoding human spasmodic
20 polypeptide (locus 10280533:957-5208).

Detailed Description

The invention provides methods and compositions useful for the treatment of a wide range of lesions to the dermis and epidermis. Lesions may occur on any part of the human skin, including for example the scalp, groin and uro-genital area, face, trunk, arms hands, legs, soles of the feet or between the toes. Lesions of the dermis and epidermis amenable to treatment according to the present invention can be induced by physical trauma (e.g., cuts, abrasions, and surgical intervention), chemical and thermal burns (e.g., sunburn), vascular compromise (e.g., resulting from diabetes), infective or inflammatory processes (e.g., eczema, psoriasis, contact dermatitis, herpetic lesion, and acne), microbial infection (e.g.,

viral, bacterial, and fungal), or antineoplastic therapy (e.g., radiotherapy). In the case of burn patients, particularly those in which skin damage inflicted by the burns is severe and extends to a large proportion of the body, epidermal loss may deteriorate rapidly due to both heat and water transpiration. Although mechanical
5 systems such as hydrogels have been used to alleviate this problem, rapid restoration of an adequate barrier is imperative for the recovery of such patients.

Preterm infants also suffer from impaired skin barrier function owing to the immature state of the epidermis and the relative absence of the stratum corneum in such infants. Although, the degree of severity is largely dependent on
10 gestational age, compromise to the skin barrier can ultimately cause significant complications. In this respect, the increased permeability of the skin to water leads to significant heat dissipation and also provides a nesting site for foreign substances, including for example allergens, microorganisms, and toxins. Overall, these lesions are treated by local application of trefoil peptides either
15 alone or in combination with another therapeutic agent.

Pharmaceutical Formulations: Ointments, Pastes, Creams, Gels, Irrigation Solutions, and Tissue Adhesives

Lesions of the epithelium of the skin, such as those resulting from trauma
20 or inflammation, are amenable to trefoil peptide therapy delivered as an ointment, paste, or gel. The viscous nature of these types of preparations allows for direct application to the wound site. Optionally, the wound site can be covered with a dressing to retain the trefoil peptide-containing composition, protect the lesion and/or absorb exudate. As discussed further below, these preparations are
25 particularly useful to restore epithelial integrity following traumatic surgical procedures (e.g., skin biopsies and incisions). Such viscous formulations may also have a local barrier effect thereby reducing irritation and pain. In addition, trefoil peptides can also be present in any of the known irrigation solutions (e.g. 0.9% saline or Ringer's solution) used for surgery purposes.

30

Mucoadhesives

A mucoadhesive excipient can be added to any of the previously described pharmaceutical compositions. The mucoadhesive formulations coat the lesioned area, resulting in retention of the trefoil peptide at the lesion site, providing protection, inhibiting irritation, and accelerating healing of inflamed or damaged tissue. Mucoadhesive formulations suitable for use in these pharmaceutical preparations are well known in the art (e.g., U.S. Patent No. 5,458,879). Particularly useful mucoadhesives are hydrogels composed of about 0.05-20% of a water-soluble polymer such as, for example, poly (ethylene oxide), poly (ethylene glycol), poly (vinyl alcohol), poly (vinyl pyrrolidine), poly (acrylic acid), poly (hydroxy ethyl methacrylate), hydroxyethyl ethyl cellulose, hydroxy ethyl cellulose, chitosan, and mixtures thereof. These polymeric formulations can also contain a dispersant such as sodium carboxymethyl cellulose (0.5-5.0%).

Other preferred mucoadhesive excipients for liquid compositions are ones that allow the composition to be administered as a flowable liquid but will cause the composition to gel on the skin, thereby providing a bioadhesive effect which acts to hold the therapeutic agents at the lesion site for an extended period of time. The anionic polysaccharides pectin and gellan are examples of materials which when formulated into a suitable composition will gel on the skin, owing to the presence of cations in the mucosal fluids. The liquid compositions containing pectin or gellan will typically consist of 0.01-20% w/v of the pectin or gellan in water or an aqueous buffer system.

Other useful compositions, which promote mucoadhesion and prolonged therapeutic retention in the dermis and epidermis, are colloidal dispersions containing 2-50% colloidal particles such as silica or titanium dioxide. Such formulations form as a flowable liquid with low viscosity; however, the particles interact with glycoprotein, especially mucin, transforming the liquid into a viscous gel, providing effective mucoadhesion (e.g., U.S. Patent Nos. 5,993,846 and 6,319,513).

30

Bioadhesives and bioerodable polymers are useful as an alternative method of wound closure, or as a drug delivery vehicle. Bioadhesives are a particularly useful alternative to sutures, for wound closure in geriatric populations, where the skin is particularly friable. Any of the well-known bioadhesives or polymers is
5 suitable for use with the trefoil peptides of this invention (e.g. U.S. Patent Nos. 5,990,194, 6,159,498, and 6,284,235). The trefoil peptides are incorporated into the adhesive or polymer by any method suitable for incorporating any other therapeutic agent into these products. The particular method will depend on the chemical composition of the product and the manufacturing process.

10

Medical Materials

Suture materials, sterile wound dressings (occlusive and semi-occlusive, e.g., gauze pads), topical patches, adhesive films, and tissue adhesives can be impregnated with the trefoil peptides of the present invention and used at an
15 incision site to promote dermal and epidermal healing. Any of the suture materials, wound dressings, topical patches, adhesive films, and tissue adhesives may also contain ITF-consisting bioerodable polymers and alginates.

These formulations can be made according to known and conventional methods for preparing such formulations. For example, sutures made from
20 monofilaments can be impregnated by loading the polymer solution with a trefoil peptide, prior to extrusion. Suture material can also be impregnated by repeated soaking/drying cycles using a trefoil peptide-containing solution. The number of cycles depends on the concentration of trefoil peptide in the soaking solution and the final amount of peptide to be contained in the suture. Soaking is a particularly
25 effective impregnation method for braided suture materials because the trefoil peptide is retained by the surface contours.

Sterile dressings and gauzes for wounds and burns, impregnated with a trefoil peptide, can also be prepared by standard methods. Typically, the trefoil peptide will be present in a viscous gel (e.g., hydrogel), separated from the
30 dermal lesion by a permeable fabric that does not adhere to the wound.

Therapeutic Agents

Trefoil Peptides

The therapeutic trefoil peptide(s) are typically mammalian trefoil peptides or fragments thereof. Preferably, human trefoil peptides or fragments are used; however, trefoil peptides from other species including rat, mouse, and non-human primate, may be used. Typically, the trefoil peptide is intestinal trefoil factor (ITF); however, spasmolytic polypeptide (SP), or pS2 are also useful.

The trefoil peptides or fragments are administered at 1-5000 mg per dose, preferably 5-2500 mg per dose, or more preferably 10-1500 mg per dose, depending on the nature and condition of the lesion being treated, the anticipated frequency and duration of therapy, and the type of pharmaceutical composition used to deliver the trefoil peptide. The trefoil peptides are typically administered 1-5 times per day.

Therapeutic Fragments of Intestinal Trefoil Factor (ITF)

Particular ITF fragments retain biological activity and may be substituted in any method or composition in which ITF is used. Methods and compositions containing ITF, in which these ITF fragments may be substituted, are described, for example, in U.S. Patent Nos. 6,063,755 and 6,221,840, and U.S. Patent Application Nos. 10/131,363, filed April 24, 2002, 60/317,657, filed September 6, 2001, 60/327,673, filed October 5, 2002, 60/333,836, filed November 28, 2001, and 60/367,574, filed March 26, 2002 (hereby incorporated by reference).

Particularly useful ITF fragments that retain biological activity include the polypeptide corresponding to amino acid residues 15-73 of SEQ ID NO:1 (ITF₁₅₋₇₃) and amino acid residues 21-73 of SEQ ID NO:1 (ITF₂₁₋₇₃). Other useful ITF fragments are formed following cleavage of the C-terminal phenylalanine residue (i.e., ITF₁₋₇₂, ITF₁₅₋₇₂, and ITF₂₁₋₇₂).

The biologically active ITF fragments of this invention can be produced using any appropriate method. For example, cDNA encoding the desired ITF fragment can be used with any method known in the art for producing recombinant proteins. Exemplary methods are provided herein. ITF fragments,

particularly ITF₂₁₋₇₃, can be produced using a *Pichia* yeast expression system (see, for example, U.S. Patent Nos. 4,882,279 and 5,122,465) transformed with a cDNA encoding long ITF species, such as the full length ITF (e.g., SEQ ID NO:4) or ITF₁₅₋₇₃, when the fermentation culture is maintained at pH ~ 5.0.

5

Anti-Inflammatory Agents

Any suitable anti-inflammatory agent can be formulated with the trefoil peptide and employed using the method of this invention. Suitable anti-inflammatory agents include, but are not limited to non-steroidal anti-inflammatory drugs (e.g., ibuprofen and tacrolimus), cyclooxygenase-2-specific inhibitors such as rofecoxib (Vioxx®) and celecoxib (Celebrex®). Anti-inflammatory concentrations known to be effective following administration can be used. For example, ibuprofen may be present in the composition at concentrations sufficient to deliver between 25-800 mg per day to the lesion.

15

Antimicrobial Agents

Any of the many known antimicrobial agents can be used in the compositions of the invention at concentrations generally used for these agents. Antimicrobial agents include antibacterials, antifungals, and antivirals.

Although the most widely used antibacterial agents used for the skin are benzoyl peroxide, povidone iodine, azelaic acid, retinoids, clindamycin and erythromycin, other examples of antibacterial agents (antibiotics) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin, and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.

30

Antiviral agents are substances capable of destroying or suppressing the replication of viruses. Examples of anti-viral agents include 1,-D-ribofuranosyl-1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine
5 arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors, attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir.

Antifungal agents include both fungicidal and fungistatic agents such as,
10 for example, benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazoles, allylamine, thicarbamates, amphotericin B, butylparaben, clindamycin, econazole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.

Antimicrobial concentrations known to be effective following topical
15 administration can be used. For example, tetracycline may be present in the composition at concentrations that are known to provide between 100-1000 mg per day to the lesion following topical application.

Analgesics and Anesthetics

20 Any of the commonly used topical analgesics can be used in the compositions of the invention. The analgesic is present in an amount such that there is provided to the skin lesion a concentration of between one-half and five percent concentration for lidocaine (e.g., 5-50 mg/ml in 20-40 ml per dose of liquid). Examples of other useful anesthetics include procaine, lidocaine,
25 tetracaine, dibucaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino) ethyl ester HCl, mepivacaine, piperocaine, and dyclonine.

Other analgesics may be administered systemically, including opioids such as, for example, morphine, codeine, hydrocodone, and oxycodone. Any of these analgesics may also be co-formulated with other compounds having analgesic or
30 anti-inflammatory properties, such as acetaminophen, aspirin, and ibuprofen.

Steroids

Steroids may be used to treat lesions of the skin and formulated to be used in the compositions of the present invention. Typically, topical steroid agents employed include but are not limited to fluocinolone, triamcinolone, betamethasone, difluocortolone, fluticasone, hydrocortisone, mometasone, methylprednisolone, and clobetasol. In extreme cases of skin irritation, systemic steroid agents such as prednisone, prednisolone, methylprednisolone, betamethasone, dexamethasone, triamcinolone, and hydrocortisone, may also be administered.

Dosages

All of the therapeutic agents employed in the topical compositions of the present invention, including the trefoil peptide component, can be used in the dose ranges currently known and used for these agents. The following are illustrative examples of dose ranges for the active ingredients of the compositions of the invention. Different concentrations of either the trefoil peptide or the other agents may be employed depending on the clinical condition of the patient, the goal of therapy (treatment or prophylaxis), and anticipated duration or severity of the damage for which the agent is being given. Additional considerations in dose selection include: disease etiology, patient age (pediatric, adult, geriatric), general health and comorbidity.

Production of Trefoil Peptides

Trefoil peptides and fragments can be produced by any method known in the art for expression of recombinant proteins. Nucleic acids that encode trefoil peptides (e.g., human intestinal trefoil factor (Figure 4 and 7), human pS2 (Figure 5 and 8), and human spasmolytic polypeptide (Figure 6 and 9) or fragments thereof may be introduced into various cell types or cell-free systems for expression thereby allowing large-scale production, purification, and patient therapy.

Eukaryotic and prokaryotic trefoil peptide expression systems may be generated in which a trefoil peptide gene sequence is introduced into a plasmid or other vector, which is then used to transform living cells. Constructs in which the trefoil peptide cDNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Prokaryotic and eukaryotic expression systems allow for the expression and recovery of trefoil peptide fusion proteins in which the trefoil peptide is covalently linked to a tag molecule, which facilitates identification and/or purification. An enzymatic or chemical cleavage site can be engineered between the trefoil peptide and the tag molecule so that the tag can be removed following purification.

Typical expression vectors contain promoters that direct the synthesis of large amounts of mRNA corresponding to the inserted trefoil peptide nucleic acid in the plasmid-bearing cells. They may also include a eukaryotic or prokaryotic origin of replication sequence allowing for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector-containing cells to be selected for in the presence of otherwise toxic drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this manner the gene product is produced on a continuous basis.

Expression of foreign sequences in bacteria, such as *Escherichia coli*, requires the insertion of a trefoil peptide nucleic acid sequence into a bacterial expression vector. Such plasmid vectors contain several elements required for the propagation of the plasmid in bacteria, and for expression of the DNA inserted into the plasmid. Propagation of only plasmid-bearing bacteria is achieved by introducing, into the plasmid, selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs. The plasmid also contains a transcriptional promoter capable of producing large

amounts of mRNA from the cloned gene. Such promoters may be (but are not necessarily) inducible promoters that initiate transcription upon induction. The plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector. Mammalian cells can also be used to
5 express a trefoil peptide. Stable or transient cell line clones can be made using trefoil peptide expression vectors to produce the trefoil peptides in a soluble (truncated and tagged) form. Appropriate cell lines include, for example, COS, HEK293T, CHO, or NIH cell lines.

Once the appropriate expression vectors are constructed, they are
10 introduced into an appropriate host cell by transformation techniques, such as, but not limited to, calcium phosphate transfection, DEAE-dextran transfection, electroporation, microinjection, protoplast fusion, or liposome-mediated transfection. The host cells that are transfected with the vectors of this invention may include (but are not limited to) *E. coli* or other bacteria, yeast, fungi, insect
15 cells (using, for example, baculoviral vectors for expression in SF9 insect cells), or cells derived from mice, humans, or other animals. *In vitro* expression of trefoil peptides, fusions, or polypeptide fragments encoded by cloned DNA may also be used. Those skilled in the art of molecular biology will understand that a wide variety of expression systems and purification systems may be used to
20 produce recombinant trefoil peptides and fragments thereof. Some of these systems are described, for example, in Ausubel *et al.* (Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY 2000, hereby incorporated by reference).

Transgenic plants, plant cells and algae are also particularly useful for
25 generating recombinant trefoil peptides for use in the methods and compositions of the invention. For example, transgenic tobacco plants or cultured transgenic tobacco plant cells expressing a trefoil peptide can be created using techniques known in the art (see, for example, U.S. Patent Nos. 5,202,422 and 6,140,075). Transgenic algae expression systems can also be used to produce recombinant
30 trefoil peptides (see, for example, Chen *et al.*, Curr. Genet. 39:365-370, 2001).

Once a recombinant protein is expressed, it can be isolated from cell lysates using protein purification techniques such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory
5 Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds., Elsevier, 1980).

Polypeptides of the invention, particularly trefoil peptide fragments can also be produced by chemical synthesis using, for example, Merrifield solid phase synthesis, solution phase synthesis, or a combination of both (see, for example,
10 the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Optionally, peptide fragments are then be condensed by standard peptide assembly chemistry.

The following examples are intended to illustrate the principle of the present invention and circumstances when trefoil peptide therapy is indicated.
15 The following examples are not intended to be limiting.

Example 1: ITF Therapy Following A Surgical Intervention

To speed healing of a surgical incision and reduce scar formation, the surgical patient is administered ITF-containing preparations using a variety of
20 modalities. Just prior to surgery, an ITF-containing gel is applied to the skin at the site of impending incision. Following the surgical procedure, the incision is irrigated with sterile saline, or another irrigation solution, containing 25 mg/ml ITF. The incision is closed using ITF-impregnated suture silk and the incision site is treated with a paste or gel preparation containing 5 mg/ml ITF. The ITF-
25 containing paste or gel is reapplied during each dressing change. Preferably, the paste or gel is reapplied for at least three days, more preferably for five days, most preferably for seven days, or even ten days, or until the incision is completely healed, and the sutures are removed or absorbed by the body.

Example 2: Burn Treatment

The ultimate goal of burn-wound management is closure and healing of the wound. In this respect, scarring is a common result of second-and third-degree burns. Given that scars are formed when the proliferative and migratory capacity of fibroblasts exceed that of the epithelial cells, therapies that promote epithelial
5 of fibroblasts exceed that of the epithelial cells, therapies that promote epithelial restitution will reduce scar formation. In addition, it is known that topical or systemic administration of an antimicrobial can dramatically decrease the bacterial burden of burn wounds and reduce the incidence of burn-wound infection.

10 Three widely used topical antimicrobial agents, namely silver sulfadiazine cream, mafenide acetate cream, and silver nitrate can be admixed, alone or in combination, with ITF to treat burn wounds. Burn victims are therefore treated with a paste or gel containing 1% silver sulfadiazine, mafenide acetate cream and/or silver nitrate, along with a topical analgesic, and 10 mg/ml ITF. Topical
15 treatment is re-applied every 12 hours for the duration of therapy. In addition to topical application of the ITF-containing ointment, the burn site may be wrapped in an ITF-impregnated bandage.

Normally, analgesic and antibiotic therapy will be terminated once satisfactory capillary development and epithelialization has occurred. In order to
20 minimize scarring, ITF therapy is continued until epithelialization is complete. In the case of invasive wound infection, systemic treatment with antibiotics along with topical treatment with ITF therapy can be administered.

Example 3: Treatment of Herpetic Lesions

25 Patients suffering lesions caused by any of the herpes simplex viruses (HSV) can be treated with combination or monotherapy containing ITF. Herpetic lesions are typically on the face or genitalia and are treated with antiviral agents. Both HSV I and HSV II are transmitted by direct contact with an open lesion, or through secondary contact with infected objects. Thus, agents that promote
30 epidermal healing will not only repair the cosmetic damage created by the lesion, it will also reduce the likelihood of viral transmission.

Presently, herpetic lesions are treated with standard antiviral therapy administered orally. According to this invention, ITF is administered concurrently in a topical preparation (e.g., paste or gel) at 5 mg/ml. Alternatively, the antiviral is coformulated with ITF for topical administration. For treatment of severe lesions, the amount of ITF can be increased to 25 mg/ml, or more, and can be further combined with medications that relieve secondary symptoms. Corticosteroids, for example, may be included in the topical preparation, to relieve itching. Typically, the medicament is applied every 12 hours to the lesion until the outbreak subsides and the lesion is resolved. The lesion can be dressed with a bandage or gauze impregnated with the antiviral and ITF as an alternative, more convenient, means of drug delivery.

Example 4: Treatment of Hand Dermatitis

Treatment of hand dermatitis is mostly concerned with avoidance of irritants, treatment of secondary infection, and reduction of inflammation. Lesions on the hand can be treated with cool dressings impregnated with trefoil peptides to dry and debride acute inflammatory lesions as well as to decrease swelling. Application of mid- to high potency topical glucocorticoid (e.g., 4% w/v hydrocortisone) formulated with 5mg/ml ITF should also be administered to lesions. The topical steroid-containing trefoil peptides can be reapplied during each dressing change, or as often as required. . The hands of an affected patient should be protected by gloves to keep the dressings, glucocorticoid, and ITF in place. If needed, a systemic steroid can also be administered. Treatment with topical antibiotics formulations containing trefoil peptides to limit secondary infections is also recommended.

What is claimed is:

CLAIMS

1. A method for treating or preventing a lesion of the skin of a mammal comprising administering to the lesion, or the region of the skin where a lesion is to be prevented, a therapeutically effective amount of a trefoil peptide or biologically active fragment thereof.
2. The method of claim 1, wherein said trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor (ITF).
3. The method of claim 1, wherein said biologically active fragment is ITF₁₅₋₇₃, ITF₂₁₋₇₃, ITF₁₋₇₂, ITF₁₅₋₇₂, or ITF₂₁₋₇₂.
4. The method of claim 1, wherein said mammal is a human.
5. The method of claim 4, wherein said human is a preterm infant.
6. The method of claim 1, wherein said lesion is a traumatic lesion, a surgical lesion, a burn, or a pressure ulcer.
7. The method of claim 1, wherein said lesion is an allergic reaction, eczema, contact dermatitis, psoriasis, or acne.
8. The method of claim 1, wherein said lesion is caused by a bacterial, viral, or fungal infection.
9. The method of claim 8, wherein said lesion is caused by a herpes virus or a papilloma virus.
10. The method of claim 1, wherein said lesion is caused by antineoplastic therapy.

11. The method of claim 1, wherein said method further comprising administering to said mammal a second therapeutic agent or regimen.

5 12. The method of claim 11, wherein said second therapeutic agent is an ultraviolet blocking agent.

13. The method of claim 11, wherein said second therapeutic agent is an anti-inflammatory agent.

10

14. The method of claim 11, wherein said second therapeutic agent is a steroid.

15. The method of claim 14, wherein said steroid is a corticosteroid.

15

16. The method of claim 14, wherein said steroid is selected from the group consisting of fluocinolone, betamethasone, diflucortolone, fluticasone, mometasone, methylprednisolone, clobetasol, glucocorticoid, triamcinolone, hydrocortisone, fluticasone, budesonide, prednisone, prednisolone,
20 methylprednisolone, dexamethasone, and beclomethasone.

17. The method of claim 11, wherein said second therapeutic agent is an antibacterial agent, an anti-fungal agent, or an anti-viral agent.

25 18. The method of claim 17, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, an aminoglycoside, benzoyl peroxide, povidone iodine, azelaic acid, retinoid, clindamycin, or erythromycin.

19. The method of claim 17, wherein said anti-fungal agent is benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazole, allylamine, thiocarbamate, clindamycin, econazole, fluconazole, flucytosine, griseofulvin, nystatin, clotrimazole, Amphotericin B, ketoconazole, enilconazole, itraconazole, butoconazole, tioconazole, or miconazole.
20. The method of claim 17, wherein said anti-viral agent is acyclovir.
21. The method of claim 11, wherein said second therapeutic agent is an analgesic agent.
22. The method of claim 21, wherein said analgesic is lidocaine, benzocaine, or an opiate.
23. The method of claim 11, wherein said second therapeutic is anthralin, a retinoid, a vitamin D analog, methotrexate, a benzodiazepine, or a cyclosporine.
24. The method of claim 11, wherein said trefoil peptide and said second therapeutic are administered in the same formulation.
25. The method of claim 11, wherein said trefoil peptide and said second therapeutic are administered in different formulations.
26. The method of claim 11, wherein said trefoil peptide and said second therapeutic are administered by different routes of administration.
27. The method of claim 11, wherein said trefoil peptide and said second therapeutic are administered within 24 hours of each other.

28. A pharmaceutical composition suitable for topical administration to the skin of a mammal, wherein said composition comprises a trefoil peptide or a biologically active fragment thereof and a pharmaceutically acceptable carrier.

5 29. The composition of claim 28, wherein said trefoil peptide or biologically active fragment thereof is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

 30. The composition of claim 28, wherein said biologically active
10 fragment is ITF₁₅₋₇₃, ITF₂₁₋₇₃, ITF₁₋₇₂, ITF₁₅₋₇₂, or ITF₂₁₋₇₂.

 31. The composition of claim 28, wherein said composition further comprises a mucoadhesive agent, or an osmotic agent.

15 32. The composition of claim 28, wherein said composition further comprises a second therapeutic agent.

 33. The composition of claim 32, wherein said second therapeutic agent is an anti-inflammatory agent, or an analgesic.

20

 34. The composition of claim 33, wherein said analgesic is lidocaine, benzocaine, or an opiate.

 35. The composition of claim 32, wherein said second therapeutic agent is
25 an antibacterial agent, an anti-fungal agent, or an anti-viral agent.

 36. The composition of claim 35, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, an aminoglycoside, benzoyl peroxide, azelaic acid, retinoids, povidone iodine, clindamycin, or erythromycin.

30

37. The composition of claim 35, wherein said anti-fungal agent is benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazole, allylamine, thiocarbamate, nystatin, clindamycin, econazole, fluconazole, flucytosine, griseofulvin, clotrimazole, ketoconazole, enilconazole, itraconazole, 5 butoconazole, tioconazole, miconazole, or Amphotericin B.

38. The composition of claim 35, wherein said anti-viral agent is acyclovir.

10 39. The composition of claim 32, wherein said second therapeutic agent is a steroid.

40. The composition of claim 39, wherein said steroid is a corticosteroid.

15 41. The composition of claim 39, wherein said steroid is fluocinolone, betamethasone, diflucortolone, fluticasone, mometasone, methylprednisolone, glucocorticoid, clobetasol, triamcinolone, hydrocortisone, fluticasone, prednisone, prednisolone, methylprednisolone, dexamethasone, beclomethasone, or budesonide.

20 42. The composition of claim 32, wherein second therapeutic agent is anthralin, a retinoid, a vitamin D analog, methotrexate, a benzodiazepine, or cyclosporine.

25 43. The pharmaceutical composition of claim 28, wherein said composition is a spray, ointment, paste, foam, lotion, gel, solution, or suspension.

44. A medical material comprising a trefoil peptide or a biologically active fragment thereof.

30

45. The medical material of claim 44, wherein said trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

46. The medical material of claim 44, wherein said biologically active
5 fragment is ITF₁₅₋₇₃, ITF₂₁₋₇₃, ITF₁₋₇₂, ITF₁₅₋₇₂, or ITF₂₁₋₇₂.

47. The medical material of claim 44, wherein said medical material is selected from the group consisting of topical hydrogel dressings, patches, occlusive wound dressings, semi-occlusive wound dressings, tissue adhesives,
10 sutures, and adhesive films.

48. The composition of claim 47, wherein said suture comprises material selected from the group consisting of gut, silk, collagen, glycolic acid polymer, and nylon.

15

20

FIGURE 1

1 MLGLVLALLS SSSAEYYVGL SANQCAVPAK DRVDCGYPHV
41 TPKECNNRGC CFDSRIPGVP WCFKPLQEAE CTF

FIGURE 2

1 MATMENKVIC ALVLVSMLAL GTLAEAQTET CTVAPRERQN
41 CGFPGVTPSQ CANKGCCFDD TVRGVPWCFY PNTIDVPPEE
81 ECEF

FIGURE 3

1 EKSPSPCQCSR LSPHNRTNCG FPGITSDQCF DNGCCFDSSV
41 TGVPWCFHPL PKQESDQCVM EVSDRRNCGY PGISPEECAS
81 RKCCFSNFIF EVPWCFFPNS VEDCHY

FIGURE 4

```
1   atgctggggc tggtcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg
61  tctgcaaacc agtgtgccgt gccagccaag gacaggggtg actgcggcta ccccatgtc
121 accccaagg agtgcaacaa ccggggctgc tgctttgact ccaggatccc tggagtgcct
181 tggtgtttca agcccctgca ggaagcagaa tgcaccttct ga
```

FIGURE 5

```
1   atggccacca tggagaacaa ggtgatctgc gccctggtcc tgggtgtccat gctggccctc
61  ggcacccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat
121 tgtgggttttc ctggtgtcac gccctcccag tgtgcaaata agggctgctg ttctgacgac
181 accgttcgtg gggccccctg gtgcttctat cctaatacca tcgacgtccc tccagaagag
241 gagtgtgaat tttag
```

FIGURE 6

```
1   atgggacggc gagacgcca gctcctggca gcgctcctcg tcctggggct atgtgccctg
61  gcggggagtg agaaaccctc cccctgccag tgctccaggc tgagcccca taacaggacg
121 aactgcggct tccctggaat caccagtga cagtgttttg acaatggatg ctgtttcgac
181 tccagtgtca ctgggggtccc ctggtgtttc caccctctcc caaagcaaga gtcggatcag
241 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa
301 tgcgcctctc ggaagtgtg cttctccaac ttcattcttg aagtgcctg gtgcttcttc
361 ccgaagtctg tggaagactg ccattactaa
```

FIGURE 7

(page 1 of 2)

```

1   atgctggggc tggctcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg
61  tgtgagtact gccctgactg ccccggtggc aggggtggcg tgaagggaag ggatccagga
121 taagggggga ttctgcattc atttaataat ggccacctgt cacatataca ctttttcctg
181 cgctagccct ttgaagtggg tctttattgt ccccathttca cagacaagga aaccgaggct
241 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgttga aatcagggtt
301 tgagcctgag cccatccccct atgaccccat agccatcttt gctggagatt tctaaattac
361 aatataggto tttatgcatt gttccacatt tacaaagaaa aaggaaagat gcaggagaaa
421 aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcattta gccattgcat
481 agcaaccctg ccatgggggtg tggctgtctc attaacccaa gtttgaagga atgagggcct
541 ggctttttatc tgggtgtctt ctgagcaggg tcaaaggcag tggttcccga acttgcagcc
601 cattagaatc acctggagag ctttaaaaaat cctaagtctt ggggcacacc agttacatca
661 gggcatctcc aggcgaagatc caggcctcag ctgttttgtt ttgagatagc cttgctttgt
721 cactcactgc tggagtgcag tggcacaaatc tcagctcact gcaacctccg cctcctgggt
781 tcaagcaatt cttgtgcctc ggcttcaagt agctgggatt acaggcatgc accaccatgc
841 ccagctaatt ttttggattt ttagtagaga tggagtttcg ctatgttggc caagctggtc
901 tcaaaactcct ggctcaagt gatcctcctg ccttggcctc ccaaagtgtc ggaattacag
961 gtgtaagcca ccatgcccag ccaacgtcag tcatttttaa agctctgcag ctgattccag
1021 tgtgagcgaa gtttggatgc caggaggata agcaattacg gactgggagc aagagaaggg
1081 aatgtaagac actgcacgtg attgccattt tcctaaggaa atactcagtt cgttaatgaa
1141 acgcagtgaa cttctgctgc acatacagac atagaggctt gcctgaaaca tgaatatatt
1201 ggggactgaa ggatgtcccg ggagggtggg acatgctcaa caattcagga aggggagatg
1261 cagaaaaaag tgaaaagcag gcagcatgcg ttgcaatgat ctctatggcg tgtgcctctc
1321 ctgtcacggg tttcatttaa aacaaagggg caaggttttg ttggtcaaac aatgaagggt
1381 aactttgttt ctgggttcaa gggaccccag attccccagg ggttcctgcc agctggaagg
1441 taccaggtc cgtatgtgac ttcccagaaa ggtgataaga gcgtgccaag gagaaagaca
1501 cttaggcaaa tggccagagt ccccgagctg agcatttaa acagctgcctc tctttaata
1561 ttcacaggga aagtgcattc tcctaagggc gagggtttca gcagtgggtg aactcggcgg
1621 ggtggggcgg agcgggagga tgcaaacttg caaagtgaag caaacacact caccgcagcc
1681 cagcaagggc tctggcagct gacagggctt tgtctgggac agctgcaaac cagtgtgccg
1741 tgccagccaa ggacagggtg gactgcggct acccccatgt caccocaaag gagtgcacaa
1801 accggggctg ctgctttgac tccaggatcc ctggagtgcc ttggtgtttc aagcccctgc
1861 aggaagcagg taaggcccca gtggcatcgt ggtctggggc cagccccata aggcaggggg
1921 tctcagggcc tccctgtcct ttctgggctg gagatggagg cacaaggacc ccaggaagcc
1981 acacacacac acctgttcca aggcctcaga gcagaggctt cacacttagg gcagccatgg
2041 ccaggggctg tcctcttctg tcccctttat gtaaaacata aaagcaattg tttcaaaaag
2101 gtgttcaaaa tgatggcatc gcatagaggg aactgattta gtaactattc ttgagagaag
2161 tggaaacgca taggtgtgga aagccggggc gacttttggg ctgtttttgc aaatcgcccc
2221 ccagagtct tgtcatttgt ggcattccct acacagacgg caggcgggtc cagccctaga
2281 cgtcaggcct cgggtgccaca cccacctcc cccactctgc ccccacaaag ggtcatctcc
2341 tctccctctc tctgccgtgg tggagggcag gtgcagggca accaccctgg gggttccctc
2401 ccagggggcg gagagcctgc gtgctgtgcg ggtaacagat ggccctgcac acgggtttgc
2461 caccctggct ccaccaggct tagctgcccc acatcgtggg tggggcgatt ggctataagc
2521 catctgccat gtccaagtgc cagctcagcc cccacgaagg ccgcacctgc gtgaggtacc
2581 ttcctggaac cagcatccag aggggcctct cttgcccttt gtccatagggt gaaatgcggg
2641 aggctgagtc ctgctggccc cggctccctg atcaatgatg ggcccctgcc cagggcctcc

```

FIGURE 7

(page 2 of 2)

```
2701 cttcacccctc cccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg
2761 agagagaggg gtctgggtac tgtccactgc cggtcctgtt ccttcagctc cactggaact
2821 acactctcct ctgagtgcc aacatggccc tgccaaggcc catctcgctt gttatctgcc
2881 tgatccctgg gtcccactat cttgcttagc aacccgaggt gggaatcttg gctattcccc
2941 catgtgggtg ggactcaaca ctccccggtg actctgggga ggaggcagca ctaggtgctg
3001 gccttggagc ctgccctgac cttgggaagc tgggcagcgt gggaggagag agactgctca
3061 cacaagcctt tgctctgttt gcagaatgca ccttctgagg cacctccagc tgccccgggc
3121 cgggggatgc gaggtcggga gcacccttgc ccggctgtga ttgctgccag gcactgttca
3181 tctcagcttt tctgtccctt tgctcccggc aagcgcttct gctgaaagtt catatctgga
3241 gcctgatgtc ttaacgaata aaggcccat gctccaccg
```

FIGURE 8

(page 1 of 2)

```

1  ccctgggggtg  cagctgagct  agacatggga  cggcgagacg  cccagctcct  ggcagcgctc
61  ctcgtccttg  ggctatgtgc  cctggcgggg  agtgagaaac  cctgtaagt  aaggagaggg
121  tctttttatg  tgctttcttt  atttctctta  aagaaaaaaa  aaaagcacia  ccataaatta
181  acttgagagg  gggaatggct  ataaaggcat  ctggcaatgt  gtgttggtca  catgggattt
241  gccactgctc  aggaggggtg  ctccaagaag  ggctccctc  ctagggaag  gctgagtgc
301  ggcaggtgtc  agcgggcccc  gtgtcgggcc  aggagggcat  tcccaccaag  ggtccttga
361  gtcccagagc  actcacctct  cgcctggatc  ttggccttgg  gtccatctgt  tcacctcct
421  ctaggagggg  tttgtttttg  tttttttccg  agacaggatc  tggctttgcc  gccaggcag
481  gagtgcagtg  gtgtgatctt  ggctcactgc  aacctctgcc  tcccaggctc  aagtgatcct
541  cccacctcag  ccgcctgagt  agctgaaacc  acagttgtgg  accatcatgc  ccggccaatt
601  tttttttttg  tattgtttgt  agagatgggg  tttcgacatg  ttgccaggga  tggctctgaa
661  ctctgagct  caagcaatct  gcccgcctcg  gcttcctaaa  gtgctgggat  tataggtag
721  agccaccatg  cctggctttt  tttttttttt  ccttttaaac  taatataaca  atttcagcaa
781  agccctatcg  gcttctcagg  aggaaaccgc  attgcttaaa  tatgggcaag  ataagacttt
841  gtgtttctct  atgtggcaac  aagacagtag  aggcattccc  tagaacctct  gagagaagga
901  gcagtgtggt  ctgggggtacc  aggggtgggg  cgactgaggg  tctttccaca  gccccctgcc
961  agtgctccag  gctgagcccc  cataacagga  cgaactgcgg  cttccctgga  atcaccagtg
1021  accagtgttt  tgacaatgga  tgctgtttcg  actccagtgt  cactgggggt  ccctgggtgt
1081  tccacccccct  cccaaagcaa  ggtaatcttc  cagggaatct  tcctgggcca  gcagctggca
1141  acccaggacc  cagcttcaca  ggcggagccc  agagcagggg  ccggaggagg  ccggttggt
1201  agtctagggt  tagcctgggt  gggttagtct  cgagctagcc  ccggttggt  agtctggggc
1261  tagcccagggt  tggttagtct  agagctagcc  caggttgggt  agtctggggc  tagcccagggt
1321  tggttagtct  ggggctagcc  caggttgggt  agtctagggc  tagttagggt  tagttagtct
1381  aaggctagcc  caggttgggt  agtttgagc  tagcgcagggt  tggttagtct  ggggctagta
1441  gcccagggtg  gttagcctgg  agctagccca  ggttggttag  tctagggcta  gcgtaggctg
1501  gttagtctgg  ggctagccca  ggttggttag  tctggagcta  gccagggtg  gttagtctgg
1561  ggctagtagc  ccaggttggt  tagtctgggg  ctagcccagg  ttggttagtc  tagggctagt
1621  gtaggctagt  tagtctaggg  ctagcccagg  ttagttagtt  tggagctagc  acaggttgat
1681  tagtctgggg  ctagtagcct  aggttggtta  gtctggagct  agcccaagtt  ggtagtcta
1741  gggctagcat  aggctgggtta  gtctggggct  agtagcctag  gtttggttagt  ctggagctag
1801  cccagggttg  ttagtctagg  gctagcgtag  gctgggttagt  ctagggttag  cccagggttg
1861  ttaatcggag  ctagcccagg  ttggttagtc  tggagctagc  ccaggttggt  tagtctgagg
1921  ctagtagccc  aggttggtta  gtctggggct  agcccagggt  tggtagtctg  gagtagccc
1981  aggttggtta  gtctggagct  agcccagggt  ggtagtctg  ggactagcct  ggactgctag
2041  tctagaggta  gcctagagga  ctgctagtct  agaggtagtc  tagggctagc  ccaggttggt
2101  tagtctgggg  ctagcccagc  ttggttagtc  ttagactagc  ctggactgct  agtctagagg
2161  tagcccagggt  tggttagtct  ggtactagcc  tggactgtta  gtctagagggt  agcccagggt
2221  ggtagggtg  gttagtctgg  gactagtctg  gactgttagt  ctagaggtag  cccagggttg
2281  ttagtctggg  actagcctgg  actgttagtc  tagaggtagc  ccagattggt  tagtctggga
2341  ctagtctgga  ctgctagtct  agaggtagcc  caggttgggt  agcctggggc  cagcctggac
2401  tgtagtcta  gaggtaaccc  aggtcagcca  acagtgagat  gaaaatttcc  cacctacct
2461  gtttctacac  tgtagttct  ttcaacagac  atgtgtgtgt  ggagccatca  gttttacttt
2521  agttgagaaa  aaaatatata  tatatatagt  aggtctcctc  tagtttttga  agtgtgactt
2581  ctgaagaagc  ttccatgggg  aaatgaagg  atttaatagg  acagcagtaa  cataaggggt
2641  gacagccctc  aaatgttagg  gaagggaagt  aagccttcta  gggttctttg  ggagtgagtt

```

FIGURE 8

(page 2 of 2)

```
2701 ttatgttagt gcacgggata aggaccaag ttgtaacgcc gacgagtgtt caaaggaagg
2761 ttgtgtgtgt gtggtgcacc tgtgtgctgt gaaccaggca cgtcctcttg agaaggagga
2821 ttcattccca agattgttgc tgggaggctt gctgggcccc gcagggaac caggcagatg
2881 gtggattgtt cactgagcgc cactgaatgg cagtgtcttt gggaatcaat accatgtcca
2941 aacgctttcc atcttaccaa ggtgccca aaccttttct catcttgcc cgggggacca
3001 cccattttac tgagaacact gagtcccgag aggcaaatg atttcccaa ggcgggggac
3061 tccagagctt ctgactgtga ccacccaca tgggccccac cttcgcgag gacaggccag
3121 ccaagcgtcg ctggggccga cacttcaca gtccccggg gaggcggtcc caggggccga
3181 cacttcaca gtccccggg gaggcgtcc cgggggatgc tgccccaggc agcacctcat
3241 gatccacgga ggctgcaaat cagcgtgtct ctgagaggag gaaggggtg agctttccag
3301 ggcacagcag gcctgactgg gtctcggtgc tgtgcctgtc ccatggcaga gtcggtatcag
3361 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa
3421 tgcgcctctc ggaagtgtct cttctccaac ttcattcttg aagtgcctg gtgcttcttc
3481 ccgaagtctg tggaggttaa cgtcgtgtg ggactctctg tctgggtccc ggacaccatg
3541 attcctctc cgtccgtaga ggtggggtgc agggagggga gctgcctcgc agcctcagtg
3601 ccatcgaggc cagggccctt gcctcctatg ggattctgaa ggcaattcca gaatgttctt
3661 ggcaaaagca gcgtcttttc aataagttta tagcctccag cattgccact gcgtcatctg
3721 tgatggctct agaaacagcg gctcatcctt gttgcctccc caggtgttg aacgttcaga
3781 ggcgttgctt gttttattgc aagcccatct gcatttgagg gctactgagt gtcttgact
3841 gtgctgggta ccagagaggg cccaactcaa gcagacctgg ccccttctcc cgtggcttcc
3901 cgttctctcc ccacatgacc ccgaatgaca aacctcatcc acaacgtcct gctccgggca
3961 gtcccgggag ggtcccgccg gcagaggtga acgggtccac ttctccacc cgcttagtga
4021 tagtgtgttc ctgactcgga gtgtggcgag gtaaaaaaag accaagcaga tccaggaaaa
4081 tggggaaaga gctactggcc cttgaaggat gccttttctt ttcttttgt taggatatca
4141 aagcactcca aagagcgaaa tatttcatgt tcaggatttt ccgagtgatt tttttatgt
4201 gacctaaagg tccacctaga aaatgttcac ttgtctgggg agaatgcgcc ccacagagga
4261 aactctggcc tgggggtggg agatttggtc cctttacacc cctccccgg gaaaggagct
4321 ctttcttcag taggaagctc ctgggcaaaag tgatgcacgc ccacccagc ttcgcagcct
4381 aggcactccc atttctgggg ttcccttacc aacctcttg catttaaact tctagactgc
4441 cattactaag agaggctggt tccagaggat gcactctggc caccgggtgt tccgaaacca
4501 aagaagaaac ttcgccttat cagcttcata cttcatgaaa tctggggtt tottaacat
4561 cttttcctca ttttcaatgg tttaacatat aatttcttta aataaaacc ttaaatctg
4621 ct
```

FIGURE 9

(page 1 of 2)

```
1 atccctgact cggggtcgcc tttggagcag agaggaggca atggccacca tggagaacaa
61 ggtgatctgc gccctggtcc tgggtgtccat gctggccctc ggcaccctgg ccgaggccca
121 gacaggtaag gcgtgcttct tcctgctctg tggggccaca gccagctctg gcagcctccg
181 ccaggagcca ctgtttttaca tacataatct tgagcacctg ttttgtgcca ggtgctgttc
241 taggccctta aaagtatatc caattttacag gatcggcaaa agcagggtgga gagtaactca
301 ggggtggcagg gcccccgag accttcgaga agtgcgacga ggagggggct gccttcagtc
361 ggggctgttt tcctgtgtta ggaagactat acaatcctcc caagtgtcat gtttcaaaga
421 ggaagtgttg gcgtggggtc tcagaatagt gcttttgact gttcatgcca acatctcccc
481 caggggcaga ccctcccaag gcccatccag ataggcccaa atgccggtcc cagtgatggc
541 cacctgggag accctctccc acaggcccgga atgcccgtcc cagtgggtggc caactgggag
601 accctctcct acagggttcct gggctccccct gggatccatg ctctgggagt caaagccacc
661 tctctcatga gtgcgtggct ggcaacccat attccctggt gttgtcaagt ggatcggttg
721 ccctgggtcc ttctagggag tggaggagga ggccattctt gcttccttgg gaagtgtttg
781 catctcaact cctttacctg cagaatggat caacgggtctg ccctagggct gtcaggaaat
841 gctgtgtggc agcatctgcg acttgcaactt tgccagctgt ggggagctga ataacttatt
901 tgccgttatt aggtacagtt tcaagggtggg ggcaggagaa agggctttct acgtttccaa
961 agcaagggtt tccagagagg cctgaagagg gagcgcccag tgggtgctgtc cgtgccccca
1021 ctgccctcca gccacctctt gatctctgct gtgggggtacc gggcctgagg ggtgggcttg
1081 ggcagcgtag aagagcagcc agcattgggc tgcagtggga agacccccaa gccatggga
1141 gggagcgggg gagcttttga acccgagaga ggaagtggcc tcggtgtaca gaacgaactg
1201 ggtgggtccc cgtgctggcc acccccaggc ccatctgcct gcgcccctgc cccacccca
1261 gccccagct ctgcccctg tgctgtggga tcacagagge cgtggcaaac tcccctccc
1321 cccccacaca ccctctggct caaggctcag agcgtctttg cgggtcactc aggtccatga
1381 tcctgttaca actgaaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa
1441 accatttcca tttatttcca tcatgcgaca aagacaaagc ggggtgggcaa gacagagtct
1501 gccggaggga gagcaccggg gctggaaatc ttctccctg aggaggaaac cccccgacc
1561 ccaggatga tgatcctccc tcaccacggg gcctctcttg acccccacag tgtcccgggg
1621 gtgggcgatg atcaccttca cgtcgcgatg gatccagacc ccaggagggc aaggttccca
1681 tggaagctgc tgggcagcgg gagctgaaca cggatccttc ccagcaagcc aggaacactt
1741 tctccaaaga catctcgagg cagtccctga tagcaaagca gacaagagaa cagcccctct
1801 cggcctcccc tggggcgccc tcacctgagc cagtgtggcc agactgagtt cctcccctcc
1861 tatgccccaa ggcagggaca gggaccggag ggtgctcttg gctcctcttt caccctctgc
1921 tgcaggctgt caaccaccag atcctaatag gttgctttct gagacctttg attccgga
1981 gctcagagcc tgaagctctg gtgttagaac ctcttgcata agatcctgcg gcagcccca
2041 gccagcccca tctgtccacg tgtcttcttc ctctagatcc ctttctctac tgccctgctt
2101 caagctgttt cacagcttgt accctctgtc ggctcctcct agaccacccc acccggtcct
2161 ctcaaccttac ctgcaatggg tttccacctc ctgaacacac ctgggtctct ggaatggcct
2221 ttgcccctgc ggctccatct tcacctggtg aacctcctcc tgcagggagc cccctgctt
2281 tgttcaacct gcttgtcatt ggctctccg gggagtgcct taccocctg gttaccctgg
2341 gcacctggg acgatggcct tgcgttgtct cgcacatgtt cttgcctttc tctccatca
2401 gatccttaga ctcttttttt ttttttttg agatggagtc ttgctctgtc actcaggctg
2461 gagtgcaatg gtgcgatctt ggctcactac aacctctgcc tcctgggttc aagtgattct
2521 cctgcctcag cctcccaagt agctgggatt acagacgtgt gccacaatgc ccgcctaatt
2581 ttttgtatct ttagtagaga tggggcttca ccattttggt caggctggtc ttgaactcct
2641 gacctcaagt gattcacctc cttcagcctc ccaaagtgtc gggattacag gcatgagcct
2701 gggcccagat atttagactc ttattaatga cttctctggt ttttaattct gggctctctc
```

FIGURE 9

(page 2 of 2)

```
2761 cacctggcac agtgccctggc ttttgccatg ctagctccca cttctcatgc acacaaatgg
2821 tgctcagtaa atatttatgt attgagtaaa atttaataat catttggtga aattaaaaag
2881 tgaataaata agttacctag aaagatgcaa agtccacaaa cctggggcac cttgcatttt
2941 ccctgagcgt aatgtttgca catcaggatg tgaggaccac gtctccctct catgtcctga
3001 ggggtttata tccgcctcac tggacagttg ctgatgtcat tggagaagga agctggatgg
3061 gtgtgtgcat gataacatca aggaattcag ccacacaactt actttgcttc ttacctgtgc
3121 actttcagag acgtgtacag tggcccccgc tgaaagacag aattgtgggt ttacctgtgt
3181 cacgccctcc cagtgtgcaa ataagggctg ctgtttcgac gacaccgttc gtggggtccc
3241 ctgggtgcttc tatcctaata ccatcgacgt ccctccagaa ggtatggcct ttttatacga
3301 tgggtttctga agatttagaa ttagttagaa aagtcattta agactacaga ggctctgatc
3361 agcatcacca gctatgcctt tacacagagt cacggccgcc agtggtgggtg caatggggta
3421 gcctgagtca ggctgcattc aggtccagga atagaaaggc agggctaagg gacttgggaa
3481 gaaacctgat ttccccccgg cttctcttca catctctaac caaaagcctg ggaagagcca
3541 ctgttggtaa cgctttctag cttgcctagg atagaggggg aaggcatgac gaaatctgaa
3601 gacatttcat gtattctttt tttttttttt tttttgaaat ggagtctcgc tccgttgccc
3661 ctgagctgga gtgcaatggg gcgatcttgg ctcaactgcaa tctctgcctc ctgagttcaa
3721 cctcagcttc ctagtagctg agattacagg tgtgtgccac tacgccagc taaatttttt
3781 ttgtattttt agtatagacg gggtttcacc atgttgcca gaccggtctt gaactcttga
3841 cctcaggtga tctgcccgcc tcagcctccc agagagctgg gattacaggc gtgagccacc
3901 gtgcccggct gacagttcat gttttctaaa gaatgtgcct atggatactt taaagtaaaa
3961 actctgtaat tgtttaaatg tgaaagaaaa tgtttatcct cactaaagca tctctttctc
4021 cctccccctc acccctgtag aggagtgtga attttagaca cttctgcagg gatctgcctg
4081 catcctgacg cgggtgccgtc ccagcacagg tgattagtcc cagagctcgg ctgccacctc
4141 caccggacac ctcagacacg cttctgcagc tgtgcctcgg ctcaaacac agattgactg
4201 ctctgacttt gactactcaa aattggccta aaaattaaaa gagatcgata tt
```

SEQUENCE LISTING

<110> The General Hospital Corporation

<120> METHODS AND COMPOSITIONS FOR TREATING
DERMAL LESIONS

<130> 50206/004WO2

<150> US 60/327,673

<151> 2001-10-05

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapien

<400> 1

Met	Leu	Gly	Leu	Val	Leu	Ala	Leu	Leu	Ser	Ser	Ser	Ser	Ala	Glu	Glu
1				5					10					15	
Tyr	Val	Gly	Leu	Ser	Ala	Asn	Gln	Cys	Ala	Val	Pro	Ala	Lys	Asp	Arg
			20					25					30		
Val	Asp	Cys	Gly	Tyr	Pro	His	Val	Thr	Pro	Lys	Glu	Cys	Asn	Asn	Arg
		35					40					45			
Gly	Cys	Cys	Phe	Asp	Ser	Arg	Ile	Pro	Gly	Val	Pro	Trp	Cys	Phe	Lys
	50					55					60				
Pro	Leu	Gln	Glu	Ala	Glu	Cys	Thr	Phe							
65						70									

<210> 2

<211> 84

<212> PRT

<213> Homo sapien

<400> 2

Met	Ala	Thr	Met	Glu	Asn	Lys	Val	Ile	Cys	Ala	Leu	Val	Leu	Val	Ser
1				5					10					15	
Met	Leu	Ala	Leu	Gly	Thr	Leu	Ala	Glu	Ala	Gln	Thr	Glu	Thr	Cys	Thr
			20					25					30		
Val	Ala	Pro	Arg	Glu	Arg	Gln	Asn	Cys	Gly	Phe	Pro	Gly	Val	Thr	Pro
		35					40					45			
Ser	Gln	Cys	Ala	Asn	Lys	Gly	Cys	Cys	Phe	Asp	Asp	Thr	Val	Arg	Gly
	50					55				60					
Val	Pro	Trp	Cys	Phe	Tyr	Pro	Asn	Thr	Ile	Asp	Val	Pro	Pro	Glu	Glu
65					70				75					80	
Glu	Cys	Glu	Phe												

<210> 3

<211> 106

<212> PRT

<213> Homo sapien

<400> 3

Glu	Lys	Pro	Ser	Pro	Cys	Gln	Cys	Ser	Arg	Leu	Ser	Pro	His	Asn	Arg
1				5					10					15	
Thr	Asn	Cys	Gly	Phe	Pro	Gly	Ile	Thr	Ser	Asp	Gln	Cys	Phe	Asp	Asn
			20					25					30		
Gly	Cys	Cys	Phe	Asp	Ser	Ser	Val	Thr	Gly	Val	Pro	Trp	Cys	Phe	His
		35					40					45			
Pro	Leu	Pro	Lys	Gln	Glu	Ser	Asp	Gln	Cys	Val	Met	Glu	Val	Ser	Asp
	50					55					60				
Arg	Arg	Asn	Cys	Gly	Tyr	Pro	Gly	Ile	Ser	Pro	Glu	Glu	Cys	Ala	Ser
65					70					75				80	
Arg	Lys	Cys	Cys	Phe	Ser	Asn	Phe	Ile	Phe	Glu	Val	Pro	Trp	Cys	Phe
				85					90					95	
Phe	Pro	Asn	Ser	Val	Glu	Asp	Cys	His	Tyr						
			100					105							

<210> 4

<211> 222

<212> DNA

<213> Homo sapien

<400> 4

atgctggggc	tggtcctggc	ottgctgtcc	tccagctctg	ctgaggagta	cgtgggcctg	60
tctgcaaacc	agtgtgccgt	gccagccaag	gacaggggtg	actgcggtta	cccccatgtc	120
accccccaagg	agtgaacaa	ccggggctgc	tgctttgact	ccaggatccc	tggagtgcct	180
tggtgtttca	agcccctgca	ggaagcagaa	tgcaccttct	ga		222

<210> 5

<211> 255

<212> DNA

<213> Homo sapien

<400> 5

atggccacca	tggagaacaa	ggtgatctgc	gccctgggtcc	tggtgtccat	gctggccctc	60
ggcacccttg	ccgaggccca	gacagagacg	tgtacagtgg	ccccccgtga	aagacagaat	120
tgtgtgtttc	ctggtgtcac	gccctcccag	tgtgcaaata	agggctgctg	tttcgacgac	180
accgttcgtg	gggtcccctg	gtgcttctat	cctaatacca	tcgacgtccc	tccagaagag	240
gagtgtgaat	tttag					255

<210> 6

<211> 390

<212> DNA

<213> Homo sapien

<400> 6

atgggacggc	gagacgcca	gctcctggca	gcgctcctcg	tcctggggct	atgtgccctg	60
gcggggagtg	agaaaccctc	cccctgccag	tgctccaggc	tgagccccc	taacaggacg	120
aactgcggct	tccctggaat	caccagtgc	cagtgttttg	acaatggatg	ctgtttcgac	180
tccagtgtca	ctgggggtccc	ctggtgtttc	cacccctccc	caaagcaaga	gtcggatcag	240
tgcgtcatgg	aggtctcaga	ccgaagaaac	tgtggctacc	cgggcatcag	ccccgaggaa	300
tgcgcctctc	ggaagtgcctg	cttctccaac	ttcatctttg	aagtgcctcg	gtgcttcttc	360
ccgaagtctg	tggaagactg	ccattactaa				390

<210> 7

<211> 3280

<212> DNA

<213> Homo sapien

<400> 7

```

atgctggggc tggctcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg 60
tgtgagtact gccctgactg ccccggtggc aggggtggcg tgaagggag ggatccagga 120
taagggggga ttctgcattc atttaataat ggccacctgt cacatataca ctttttcctg 180
cgctagccct ttgaagtggg tctttattgt ccccatttca cagacaagga aaccgagggt 240
cagagaaaag taacaactta tccaaggcag cctgcccag tctgtgttga aatcagggtt 300
tgagcctgag cccatccctt atgaccccat agccatcttt gctggagatt tctaaattac 360
aatataggtc tttatgcatt gttccacatt tacaagaaa aaggaaagat gcaggagaaa 420
aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcattta gccattgcat 480
agcaaccctg ccatggggtg tggctgtctc attaacccaa gtttgaagga atgagggtcat 540
ggcttttatc tgggtgtctt ctgagcaggg tcaaaggcag tggttccga acttgcagcc 600
cattagaatc acctggagag ctttaaaaa cctaattgct ggggcacacc agttacatca 660
gggcatctcc aggaagatc caggcctcag ctgttttgtt ttgagatagc cttgctttgt 720
gactcactgc tggagtgcag tggcacact tcagctcact gcaacctccg cctcctgggt 780
tcaagcaatt cttgtgcctc ggcttcaagt agctgggatt acaggcatgc accaccatgc 840
ccagctaatt ttttgattt ttagtagaga tggagtttcg ctatgttggc caagctggtc 900
tcaaactcct ggctcaagt gatcctcctg ccttggcctc ccaaagtgtt ggaattacag 960
gtgtaagcca ccatgcccag ccaacgtcag tcatttttaa agctctgcag ctgattccag 1020
tgtgagcgaa gtttgatgc caggaggata agcaattacg gaactgggagc aagagaaggg 1080
aatgtaagac actgcacgtg attgccattt tcctaaggaa atactcagtt cgttaatgaa 1140
acgcagtga cttctgtgc acatacagac atagaggctt gcctgaaaca tgaaaaattt 1200
ggggactgaa ggatgtcccg ggagggtggg acatgctcaa caattcagga agggagatg 1260
cagaaaaaag tgaaaagcag gcagcatgcg ttgcaatgat ctctatggcg tgtgcctctc 1320
ctgtcacggg tttcatttaa acaaaagggg caaggttttg ttggtcaaac aatgaaggg 1380
aactttgtt ctgggttcaa gggaccccag attccccagg ggttcctgcc agctggaagg 1440
taccaggtc cgtatgtgac ttcccagaaa ggtgataaga gcgtgccaa gagaagaca 1500
cttaggcaa tggccagagt ccccgagctg agcatttaac agactgcctc tctttaata 1560
ttcacaggga aagtgcattc tcctaagggc gagggtttca gcagtggttg aactcggcg 1620
gggtggggcg agcgggagga tgcaaacttg caaagtgaag caaacacact caccgcagcc 1680
cagcaagggc tctggcagct gacagggtt tgtctgggac agctgcaaac cagtgtgccc 1740
tgccagccaa ggacagggtg gactgcggct acccccatgt caccccaag gagtgcaca 1800
accggggctg ctgctttgac tccaggatcc ctggagtgc ttggtgtttc aagcccctgc 1860
aggaagcagg taaggcccca gtggcatcgt ggtctgggcc cagcccata aggcagggg 1920
tctcagggcc tccctgtcct ttctgggctg gagatggagg cacaaggacc ccaggaagcc 1980
acacacacac acctgttcca aggcctcaga gcagaggctt cacacttagg gcagccattg 2040
ccagggcggt tccctctctg tcccctttat gtaaaacata aaagcaattg tttcaaaag 2100
gtgttcaaaa tgatggcatc gcatagaggg aactgattta gtaactattc ttgagagaag 2160
tggaacgca taggtgtgga aagccgggcc gacttttggg ctgtttttgc aaatcgccc 2220
cccagagtct tgtcatttgt ggcattccct acacagacgg caggcgggtc cagccctaga 2280
cgtcaggcct cgggtgcaca cccacctcc cccactctgc ccccacaag ggtcatctcc 2340
tctccctctc tctgccgtgg tggagggcag gtgcagggca accacctgg gggttccctc 2400
cccaggggcg gagagcctgc gtgctgtgcg ggtaacagat ggccctgcac acgggtttgc 2460
caccctggct ccaccaggct tagctgcccc acatcgtggg tggggcgatt ggctataagc 2520
catctgccat gtccaagtgc cagctcagcc cccaagaagg ccgcacctgc gtgaggtacc 2580
ttcctggaac cagcatccag aggggcctct cttgcccttt gtcctaggtt gaaatgcggg 2640
aggctgagtc ctgctggccc cggctccctg atcaatgatg ggccctgcc cagggcctcc 2700
cttcaccctc ccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg 2760
agagagaggg gtctggctac tgtccactgc cggtoctgtt ccttcagctc cactggaact 2820
acactctcct ctgagtcca gccatggccc tgccaaggcc catctcgctt gttatctgcc 2880
tgatccctgg gtccactat cttgcttagc aacccgaggt gggaatcttg gctattcccc 2940
catgtggtgg ggactcaaca ctcccgggtg actctgggga ggaggcagca ctagggtctg 3000
gccttgagc ctgccctgac cttgggaagc tgggcagcgt ggggtggagag agactgctca 3060
cacaagcctt tgctctgttt gcagaatgca cctctgagg cacctccagc tgccccggc 3120
cgggggatgc gaggtcggga gcacccttgc ccggtgtgta ttgctgccag gcactgttca 3180
tctcagcttt tctgtccctt tgctcccgcc aagcgtctct gctgaaagtt catatctgga 3240

```

gcctgatgtc ttaacgaata aagggtcccat gctccacccg

3280

<210> 8

<211> 4623

<212> DNA

<213> Homo sapien

<400> 8

dccctggggt	gcagctgagc	tagacatggg	acggcgagac	gcccagctcc	tggcagcgct	60
cctcgctcctg	gggctatgtg	ccctggcggg	gagtgagaaa	ccctgtaagt	gaaggagagg	120
gtctttttat	gtgctttctt	tatttctctt	aaagaaaaaa	aaaaagcaca	accataaatt	180
aacttgagag	ggggaatggc	tataaaggca	tctggcaatg	tgtgttggtc	acatgggatt	240
tgccactgct	caggaggggtg	gctccaagaa	gggcctccct	cctagggaaa	ggctgagtga	300
cggcaggtgt	cagcggggcc	cgtgtcgggc	caggagggca	ttcccaccaa	gggtccttgg	360
agtcccagag	cactcacctc	tcgcctggat	cttggccttg	ggtccatctg	ttcaccctcc	420
tctaggaggg	ttttgttttt	gtttttttcc	gagacaggat	ctggctttgc	cgcccaggca	480
ggagtgcagt	gggtgtgatct	tggctcactg	caacctctgc	ctcccaggct	caagtgatcc	540
tcccacctca	gccgcctgag	tagctgaaac	cacagttgtg	gaccatcatg	cccgcccaat	600
tttttttttt	gtattgtttg	tagagatggg	gtttcgacat	gttgcccagg	atggtcttga	660
actcctgagc	tcaagcaatc	tgcccgcctc	ggcttcctaa	agtgtcggga	ttataggtat	720
gagccaccat	gcctggcttt	tttttttttt	tcctttttaa	ctaataataa	aatttcagca	780
aagccctatc	ggcttctcag	gaggaaaccg	cattgcttaa	atatgggcaa	gataagactt	840
tgtgtttctc	tatgtggcaa	caagacagta	gaggcatccc	ctagaacctc	tgagagaagg	900
agcagtgtgg	tctggggtag	caggggtggg	ccgactgagg	gtctttccac	agccccctgc	960
cagtgtctca	ggctgagccc	ccataacagg	acgaactgcg	gcttccctgg	aatcaccagt	1020
gaccagtgtt	ttgacaatgg	atgctgtttc	gactccagtg	tcactggggg	cccctgggtg	1080
ttccaccccc	tcccaaagca	aggtaatctt	ccagggaatc	ttcctggggc	agcagctggc	1140
aaccaggagc	ccagcttcac	aggcggagcc	cagagcaggg	gccggaggag	gcccagttgc	1200
tagtctaggg	ttagcctggg	tgggttagtc	tcgagctagc	cccggttggg	tagtctgggg	1260
ctagcccagg	ttggttagtc	tagagctagc	ccaggttggg	tagtctgggg	ctagcccagg	1320
ttgggttagtc	tggggctagc	ccaggttggg	tagtctaggg	ctagtgtagg	ctagttagtc	1380
taaggctagc	ccaggttggg	tagtttggag	ctagcgcagg	ttgggttagtc	tggggctagt	1440
agcccagggt	gggttagcctg	gagctagccc	aggttgggtt	gtctaggggt	agcgtagggt	1500
gggttagtctg	gggctagccc	aggttgggtt	gtctggagct	agcccagggt	gggttagtctg	1560
gggctagtag	cccagggttg	ttagttctggg	gctagcccag	gttgggttagt	ctagggctag	1620
tgtaggctag	ttagttctagg	gctagcccag	gttagttagt	ttggagctag	cacaggttga	1680
ttagttctggg	gctagtagcc	taggttgggt	agtctggagc	tagcccaagt	tgggttagtct	1740
agggctagca	taggctgggt	agtctggggc	tagtagccta	ggtttggtag	tgtggagtag	1800
gcccagggtt	gttagtctag	ggctagccta	ggctgggttag	tctaggggta	gcccagggtt	1860
gttaatcgga	gctagcccag	gttgggttagt	ctggagctag	cccagggttg	ttagttctgag	1920
gctagtagcc	cagggttgggt	agtctggggc	tagcccagggt	ttgttagtct	ggagctagcc	1980
cagggttgttt	agtctggagc	tagcccagggt	tgggttagtct	gggactagcc	tggactgcta	2040
gtctagaggt	agcctagagg	actgctagtc	tagaggtagt	ctagggctag	cccagggttg	2100
ttagttctggg	gctagcccat	gttgggttagt	cttagactag	cctggactgc	tagtctagag	2160
gtagcccagg	ttgttttagtc	tggtagtagc	ctggactgtt	agtctagagg	tagcccagggt	2220
tgggttaggtt	gggttagtctg	ggactagtct	ggactgttag	tctagaggta	gcccagggtt	2280
gttagtctgg	gactagcctg	gactgttagt	ctagaggtag	cccagattgg	ttagttctggg	2340
actagtctgg	actgctagtc	tagaggtagc	ccaggttggg	tagcctgggg	ccagcctgga	2400
ctgttagtct	agaggttaacc	cagggtcagcc	aacagtgaga	tgaaaatttc	ccacctaccc	2460
tgtttctaca	ctgttagttc	tttcaacaga	catgtgtgtg	tggagccatc	agttttactt	2520
tagttgagaa	aaaaatatat	atatatatag	taggtctcct	ctagtttttg	aagtgtgact	2580
tctgaagaag	cttccatggg	gaaatgaagg	tatttaatat	gacagcagta	acataagggc	2640
tgacagccct	caaatgttag	ggaagggaagt	gaagccttct	agggttcttt	gggagttagt	2700
tttatgttag	tgcacgggat	caggacccaa	gttgtaacgc	cgacgagtg	tcaaagggaag	2760
gttgtgtgtg	tgtcgtgcac	ctgtgtgcgt	ggaaccaggc	acgtcctctg	gagaaggagg	2820
attcatcccc	aagattgttg	ctgggaggct	tgtctggccc	cgcagggaaa	ccaggcagat	2880
gggtgattgt	tcacgagcgc	ccactgaatg	gcagtgtctt	tgggaatcaa	taccatgtcc	2940
aaacgctttc	catcttacca	aggtgccccac	aaaccttttc	tcactctggc	ccgggggacc	3000

accccatTTTA	ctgagaacac	tgagtcccgA	gaggcAAAAT	gatttcccca	aggcggggga	3060
ctccagagct	tctgactgtg	accaccccac	atgggccccA	ccttcgcgga	ggacaggcca	3120
gccaaagcgtc	gctggggccg	acacttccac	agtccccggg	ggaggcggtc	ccaggggccg	3180
acacttccac	agtccccggg	ggaggccgtc	ccgggggatg	ctgccccagg	cagcacctca	3240
tgatccacgg	aggctgcaaa	tcagcgtctg	tctcagagga	ggaaggggtg	gagctttcca	3300
gggcacagca	ggcctgactg	ggtctcggtg	ctgtgcctgt	cccatggcag	agtcggatca	3360
gtgcgtcatg	gaggtctcag	accgaagaaa	ctgtggctac	ccgggcacac	gccccgagga	3420
atgcgcctct	cggaaagtgt	gcttctccaa	cttcatcttt	gaagtgcctt	ggtgcttctt	3480
ccgaaagtct	ctggaaggta	acgtcgtctg	gggactctct	gtctgggtcc	cggacaccat	3540
gattcctcct	ccgtccgtag	aggtgggggtg	caggggagggg	agctgcctcg	cagcctcagt	3600
gccatcgagg	ccaggggccc	tgcctcctat	gggattctga	aggcaattcc	agaatgttct	3660
tggcaaagac	agcgtctttt	caataagttt	atagcctcca	gcattgccac	tgcgtcatct	3720
gtgatggctc	tagaaaacagc	ggctcatccc	tgttgccctc	ccagggtgtg	caacgttcag	3780
aggcgttgcc	tgttttattg	caagcccata	tgcatttgga	ggctactgag	tgtcttgcac	3840
tgtgctgggt	accagagagg	gcccactcca	agcagacctg	gccccctctc	ccgtggcttc	3900
ccgttctctc	cccacatgac	ccgaatgac	aaacctcacc	cacaacgtcc	tgctccgggc	3960
agtccccgga	gggtcccgcc	ggcagagggtg	aacgggtcca	cttctcccac	ccgttagtg	4020
atagtgtgtt	cctgactcgg	agtgtggcga	ggtaaaaaaa	gaccaagcag	atccaggaaa	4080
atggggaaaag	agctactggc	ccttgaagga	tgccttttct	tttctttttg	ttaggataatc	4140
aaagcactcc	aaagagcgaa	atatttcatg	ttcaggattt	tccgagtgat	tttttttatg	4200
tgaacctaaa	gtccacctag	aaaatgttca	cttgtctggg	gagaatgcgc	cccacagagg	4260
aaactctggc	ctgggggtggg	aagatttggt	cccttttacac	ccccctcccc	ggaaaggagc	4320
tccttcttca	gtaggaaagt	cctggggcaaa	gtgatgcacg	cccaccccag	cttcgcagcc	4380
taggcactcc	catttctggg	gttcccttac	caaccatctt	gcattttaa	ttctagactg	4440
ccattactaa	gagaggctgg	ttccagagga	tgcattctggc	tcaccgggtg	ttccgaaacc	4500
aaagaagaaa	cttcgcctta	tcagcttcat	acttcatgaa	atcctgggtt	ttcttaacca	4560
tcttttcctc	attttcaatg	gtttaacata	taatttcttt	aaataaaacc	cttaaaatct	4620
gct						4623

<210> 9

<211> 4252

<212> DNA

<213> Homo sapien

<400> 9

atccctgact	cgggggtcgcc	tttggagcag	agaggaggca	atggccacca	tggagaacaa	60
ggtgatctgc	gccctgggtcc	tggtgtccat	gctggccctc	ggcaccctgg	ccgaggccca	120
gacaggtaag	gcgtgcttct	tctgctctg	tggggccaca	gccagctctg	gcagcctccg	180
ccaggagcca	ctgtttttaca	tacatatctt	tgagcacctg	ttttgtgcca	ggtgctgttc	240
taggccttta	aaagtatatc	caattttacag	gatcggcaaa	agcagggtga	gagtaactca	300
gggtggcagg	gcccccgag	accttcgaga	agtgcgacga	ggaggggggt	gccttcagtc	360
ggggctgttt	tcctgtgtta	ggaagactat	acaatcctcc	caagtgtcat	gtttcaaaga	420
ggaagtgttg	gcgtgggggtc	tcagaatagt	gcttttgact	gttcatgcc	acatctcccc	480
caggggcaga	ccctcccaag	gcccattccag	ataggcccaa	atgccgggtc	cagtgatggc	540
cacctgggag	accctctccc	acaggccccga	atgcccggtc	cagtgggtgc	caactgggag	600
accctctcct	acagggttcc	gggctccct	gggatccatg	ctctgggagt	caaagccacc	660
tctctcatga	gtgcgtgggt	ggcaacccat	attccctggg	gttgtcaagt	ggatcggttg	720
ccctgggtcc	ttctagggag	tggaggagga	ggccattctt	gcttccttgg	gaagtgtttg	780
catctcaact	cctttacctg	cagaatggat	caacgggtctg	ccctaggggt	gtcaggaaat	840
gctgtgtggc	agcatctgog	acttgcactt	tgccagctgt	ggggagctga	ataacttatt	900
tgccgttatt	aggtacagtt	tcaagggtggg	ggcaggagaa	agggctttct	acgtttccaa	960
agcaagggtt	tcagagaggg	cctgaagagg	gagcgcgccag	tggtgctgtc	cgtgccccca	1020
ctgccctcca	gccacctctt	gatctctgct	gtggggtagc	gggcctgagg	ggtgggcttg	1080
ggcagcgtag	aagagcgacc	agcattgggc	tgcagtggga	agacccccaa	gccccatgga	1140
gggagcgggg	gagcttttga	acccgagaga	ggaagtggcc	tcgggtgtaca	gaacgaaactg	1200
ggtgggtccc	cgtgctggcc	acccccaggc	ccatctgcct	gcgcccttgc	ccccaccccc	1260
gccccagct	ctgccccctg	tgctgtggga	tcacagaggc	cgtggcaaac	tccccctccc	1320
acccccacaca	ccctctgggt	caaggctcag	agcgtctttg	cgggtcactc	aggtccatga	1380

tcctgttaca	actgaaatct	agaaaattgt	gattacagtt	tagtgcatte	gtgtgtggaa	1440
accattttcca	tttattttcca	tcattgcgaca	aagacaaaagc	gggtggggcaa	gacagagtct	1500
gccggaggga	gagcaccggg	gctggaaaatc	ttcctccctg	aggaggaaac	ccccccgacc	1560
cccaggatga	tgatcctccc	tcaccacggg	gcctctcttg	acccccacag	tgctccgggg	1620
gtgggcatg	atcaccttca	cgtcgcatg	gatccagacc	ccaggaggggc	aaggttccca	1680
tggaagctgc	tgggcagcgg	gagctgaaca	cggatccttc	ccagcaagcc	aggaacactt	1740
tctccaaaga	catctcgagg	cagtccctga	tagcaaagca	gacaagagaa	cagccccctt	1800
cggcctcccc	tggggcgccc	tcacctgagc	cagtgtggcc	agactgagtt	cctccccctc	1860
tatgccccaa	ggcagggaca	gggaccggag	ggtgctctgg	gctcctcttt	cacccccctg	1920
tgcaggctgt	caaccaccag	atcctaatag	gttgcctttt	gagacctttg	attccggcga	1980
gctcagagcc	tgaagctctg	gtgttagaac	ctcttgcata	agatcctgcg	gcagccccca	2040
gccagcccca	tctgtccacg	tgtcttcctc	ctctagatcc	ctttcctcac	tgccctgctt	2100
caagctgttt	cacagcttgt	accctctgtc	ggctcctcct	agaccacccc	acccggctct	2160
ctcaccttac	ctgcaatggg	tttccacctc	ctgaacacac	ctgggtctct	ggaatggcct	2220
ttgcccattg	ggctccatct	tcacctgggt	aacctcctcc	tgcagggagc	ccccctgctt	2280
tgttcaacct	gcttgtcatt	ggcctctccg	gggagtgccc	tacccccgtg	gttaccttgg	2340
gcaccctggg	acgatggcct	tgcgttgtct	cgcacatgtt	cttgcccttc	tcctccatca	2400
gacccctaga	ctcttttttt	tttttttttg	agatggagtc	ttgctctgtc	actcaggctg	2460
gagtgcattg	gtgcgatctt	ggctcactac	aacctctgcc	tcctgggttc	aagtgattct	2520
cctgcctcag	cctcccaagt	agctgggatt	acagacgtgt	gccacaatgc	ccgcctaatt	2580
ttttgtatth	ttagtagaga	tggggcttca	ccatttttgt	caggctgggtc	ttgaactcct	2640
gacctcaagt	gattcacctc	cttcagcctc	ccaaagtgtc	gggattacag	gcctgagcct	2700
gggcccagat	atttagactc	ttattaatga	cttctctggg	tttaatttct	gggtctctct	2760
caaccctgac	agtgcctggc	ttttgccatg	ctagctccca	cttctcatgc	acacaaaatg	2820
tgctcagtaa	atatttatgt	attgagtaaa	atttaataat	catttgttga	aattaaaaag	2880
tgaataaata	agttacctag	aaagatgcaa	agtccacaaa	cctggggcac	cttgcattht	2940
ccctgagcgt	aatgtttgca	catcaggatg	tgaggaccac	gtctccctct	catgtcctga	3000
gggtttttata	tcgcctcac	tggacagttg	ctgatgtcat	tggagaagga	agctggatgg	3060
gtgtgtgcat	gataacatca	aggaattcag	cccacaactt	actttgcttc	ttacctgtgc	3120
actttcagag	acgtgtacag	tggccccccg	tgaagacag	aattgtgggt	ttcctgggtg	3180
caagccctcc	cagtgtgcaa	ataagggtg	ctgtttcgac	gacaccgttc	gtggggtccc	3240
ctgggtgcttc	tatcctaata	ccatcgacgt	ccctccagaa	ggtatggcct	ttttatacga	3300
tgggttctga	agatttagaa	ttagttagaa	aagtcattta	agactacaga	ggctctgatc	3360
agcatcacca	gctatgcctt	tacacagagt	cacggccgcc	agtgggtggg	caatggggta	3420
gcctgagtca	ggctgcattc	aggtccagga	atagaaaggc	agggctaagg	gacttgggaa	3480
gaaacctgat	ttccccccgg	cttctcttca	catctctaac	caaaagcctg	ggaagagcca	3540
ctgttggttaa	cgctttctag	cttgccctagg	atagaggggg	aaggcatgac	gaaatctgaa	3600
gacatttcat	gtattctttt	tttttttttt	tttttgaaat	ggagtctcgc	tcctgtgccc	3660
ctgagctgga	gtgcaatggg	gcgatcttgg	ctcactgcaa	tctctgcctc	ctgagttcaa	3720
cctcagcttc	ctagtagctg	agattacagg	tgtgtgccac	tacgcccagc	taaatttttt	3780
ttgtattttt	agtatagacg	gggtttcacc	atgttggcca	gaccggtctt	gaactcttga	3840
cctcaggtga	tctgcccggc	tcagcctccc	agagagctgg	gattacaggc	gtgagccacc	3900
gtgcccggct	gacagttcat	gttttctaaa	gaatgtgcct	atggataact	taaagtaaaa	3960
actctgtaat	tgtttaaatg	tgaagaaaaa	tgtttatcct	cactaaagca	tctctttctc	4020
cctccccctc	acccctgtag	aggagtgtga	atthttagaca	cttctgcagg	gatctgcctg	4080
catcctgacg	cggtgccgtc	cccagcacgg	tgattagtcc	cagagctcgg	ctgccacctc	4140
caccggacac	ctcagacacg	cttctgcagc	tgtgcctcgg	ctcacaacac	agattgactg	4200
ctctgacttt	gactactcaa	aattggccta	aaaattaaaa	gagatcgata	tt	4252